Antibody Drug Conjugates (ADCs)

Characterization of ADCs As biopharmaceutical organizations explore the use of Antibody Drug Conjugates (ADC) as a class of

cancer therapies, significant challenges are found in analyzing their complex, heterogeneous structures. The determination of drug-to-antibody ratios (DAR) and sites of conjugation present unique analytical challenges that can be addressed with Waters' fit-for-purpose UPLC, QTof MS and informatics solutions.

About Us

Malva continuously strives to maintain leadership in all aspects of its analytical solutions portfolio

Stay Connected on:


Contact us

Please feel free to contact us at:

 This email address is being protected from spambots. You need JavaScript enabled to view it.
(+30) 210-8000904
(+30) 210-8001424
Athens: 13 Ilission, Ν. Kifissia 14564
Thessaloniki: 26 D. Glinou, 54249